Assessment of treatment outcomes in patients with overactive bladder: Importance of objective and subjective measures

Urology

Volumn 68, Issue 2 SUPPL., 2006, Pages 17-28

  Abrams, Paul ^a   Artibani, Walter ^b   Gajewski, Jerzy B ^c   Hussain, Iqbal ^d  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c DALHOUSIE UNIVERSITY   (Canada)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPANTHELINE BROMIDE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ARTICLE; BLADDER CAPACITY; CLINICAL TRIAL; DAILY LIFE ACTIVITY; EVALUATION; HUMAN; LIFESTYLE; META ANALYSIS; MICTURITION; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PERCEPTION; PRIORITY JOURNAL; QUALITY OF LIFE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URODYNAMICS;

CONTROLLED CLINICAL TRIALS; HEALTH STATUS; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC;

EID: 33746883214     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.05.044     Document Type: Article

References (46)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology in lower urinary tract function. report from the standardisation sub-committee of the International Continence Society. Urology 61 (2003) 37-49
2. Coyne K., Payne C., Bhattacharyya S., et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder. results from a national community survey. Value Health 7 (2004) 451-459
3. Liberman J.N., Hunt T.L., Stewart W.F., et al. Health-related quality of life among adults with symptoms of overactive bladder. results from a U.S. community-based survey. Urology 57 (2001) 1044-1050
4. Rogers R., Margolis M.K., Bavendam T., et al. Overactive bladder with urinary incontinence adversely affects women's sexual quality of life (2005) Presented at the XXth Congress of the European Association of Urology; March 16-19, Istanbul, Turkey.
5. Milsom I., Irwin D.E., Kopp Z., et al. Impact of overactive bladder symptoms on employment, daily life, and emotional well-being among European men and women (2005) Presented at the XXth Congress of the European Association of Urology; March 16-19, Istanbul, Turkey.
6. Khullar, V, Chapple C, Gabriel Z, et al: The effects of antimuscarinics on quality of life in overactive bladder: a systematic review and meta-analysis. Urology. In press.
7. Wiklund I. Assessment of patient-reported outcomes in clinical trials. the example of health-related quality of life. Fundam Clin Pharmacol 18 (2004) 351-363
8. Fairclough D.L. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 13 (2004) 115-138
9. Coyne K.S., and Kelleher C.J. Clinical versus patient outcomes. whose outcome has greater value?. BMJ (2003) [online; rapid response] Nov
10. DuBeau C.E., Levy B., Mangione C.M., et al. The impact of urge urinary incontinence on quality of life. importance of patients' perspective and explanatory style. J Am Geriatr Soc 46 (1998) 683-692
11. Donovan J., Badia X., Corcos J., et al. Committee 6. symptom and quality of life assessment. In: Abrams P., Cardozo L., Khoury S., et al. (Eds). Incontinence (2002), Plymbridge Distributors, Ltd, Plymouth, United Kingdom 267-316
12. Marschall-Kehrel D., Roberts R.G., and Brubaker L. Patient-reported outcomes in overactive bladder. the influence of perception of condition and expectation for treatment benefit. Urology 68 suppl 2A (2006) 29-37
13. Coyne K.S., Matza L.S., and Thompson C.L. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14 (2005) 849-855
14. Chapple C., Khullar V., Gabriel Z., et al. The effects of antimuscarinic treatments in overactive bladder. a systematic review and meta-analysis. Eur Urol 48 (2005) 5-26
15. Alloussi S., Luval K.-U., Eckert R., et al. Trospium chloride in patients with motor urge syndrome (detrusor instability). a double-blind, randomized, multicentre, placebo-controlled study. J Clin Res 1 (1998) 439-451
16. Brambila E.A.S., Avila R.G.Q., Monterrubio J.L.L., et al. Evaluation of the effectiveness and tolerance of oxybutynin in the treatment of unstable bladder in women. [translated from Spanish]. Ginecol Obstet Mex 68 (2000) 174-181
17. Burgio K.L., Locher J.L., Roth D.L., et al. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. J Gerontol B Psychol Sci Soc Sci 56 (2001) P46-P51
18. Cardozo L., Chapple C.R., Toozs-Hobson P., et al. Efficacy of trospium chloride in patients with detrusor instability. a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 85 (2000) 659-664
19. Dmochowski R.R., Davila G.W., Zinner N.R., et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 168 (2002) 580-586
20. Halaska M., Dorschner W., and Frank M. Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourol Urodyn 13 (1994) 428-430
21. Jünemann K.P., Hessdoerfer E., Unamba-Oparah I., et al. Propiverine hydrochloride immediate (IR) and extended release (ER). comparison of efficacy and tolerability in patients with overactive bladder (2004) Presented at the 34th Meeting of the International Continence Society; August 23-27, Paris, France. Abstract 143.
22. Khullar V., Hill S., Laval K.-U., et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release. a randomized, placebo-controlled trial. Urology 64 (2004) 269-275
23. Millard R., Tuttle J., Moore K., et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 161 (1999) 1551-1555
24. Moore K.H., Hay D.M., Imrie A.E., et al. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 66 (1990) 479-485
25. Rentzhog L., Stanton S.L., Cardozo L., et al. Efficacy and safety of tolterodine in patients with detrusor instability. a dose-ranging study. Br J Urol 81 (1998) 42-48
26. Rudy D., Cline K., Goldberg K., et al. A multicenter randomised, placebo-controlled trial of trospium chloride in overactive bladder patients (2004) Presented at the 34th Meeting of the International Continence Society; August 23-27, Paris, France. Abstract 144.
27. Steers W., and Corcos J. Efficacy, tolerability, and safety of darifenacin, an M3 selective antagonist for the treatment of overactive bladder, using a flexible dosing regimen. Prog Urol 14 suppl 3 (2004) 68
28. Szonyi G., Collas D.M., Ding Y.Y., et al. Oxybutynin with bladder retraining for detrusor instability in elderly people. a randomized controlled trial. Age Ageing 24 (1995) 287-291
29. Zinner N., Gittelman M., Harris R., et al. Trospium chloride improves overactive bladder symptoms. a multicenter phase III trial. J Urol 171 (2004) 2311-2315
30. Abrams P., Larsson G., Chapple C., et al. Factors involved in the success of antimuscarinic treatment. BJU Int 83 suppl2 (1999) 42-47
31. Burgio K.L., Locher J.L., Goode P.S., et al. Behavioral vs drug treatment for urge urinary incontinence in older women. a randomized controlled trial. JAMA 280 (1998) 1995-2000
32. Derogatis L.R., Rickels K., and Rock A.F. The SCL-90 and the MMPI. a step in the validation of a new self-report scale. Br J Psychiatry 128 (1976) 280-289
33. Barkin J., Corcos J., Radomski S., et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 26 (2004) 1026-1036
34. Davila G.W., Daugherty C.A., and Sanders S.W. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 166 (2001) 140-145
35. Halaska M., Ralph G., Wiedemann A., et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20 (2003) 392-399
36. Malone-Lee J., Shaffu B., Anand C., et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 165 (2001) 1452-1456
37. Abrams P., Freeman R., Anderstrom C., et al. Tolterodine, a new antimuscarinic agent. as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81 (1998) 801-810
38. Chapple C.R., Arano P., Bosch J.L., et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 93 (2004) 71-77
39. Dmochowski R.R., Sand P.K., Zinner N.R., et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62 (2003) 237-242
40. Homma Y., Paick J.S., Lee J.G., et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder. a randomized, placebo-controlled trial. BJU Int 92 (2003) 741-747
41. Lee J.G., Hong J.Y., Choo M.S., et al. Tolterodine. as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 9 (2002) 247-252
42. Leung H.Y., Yip S.K., Cheon C., et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 90 (2002) 375-380
43. Madersbacher H., Halaska M., Voigt R., et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84 (1999) 646-651
44. Thuroff J.W., Bunke B., Ebner A., et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity. oxybutynin versus propantheline versus placebo. J Urol 145 (1991) 813-816 discussion 816-817
45. Kelleher C.J., Cardozo L.D., Khullar V., et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104 (1997) 1374-1379
46. Michel M.C., Oelke M., Goepel M., et al. What determines patient satisfaction in the treatment of overactive bladder? (2005) Presented at the 35th Annual Meeting of the International Continence Society; August 28 to September 2, Montreal, Quebec, Canada.